Seattle Genetics, Inc. Highlights Updated Progression-Free Survival And Overall Survival Data From ADCETRIS® (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial At The ESMO 2014 Congress

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted ADCETRIS (brentuximab vedotin) data to be presented at the 2014 European Society for Medical Oncology (ESMO) Congress being held September 26-30, 2014 in Madrid, Spain. The data include a two-year durability analysis from a phase 1 clinical trial of ADCETRIS in combination with chemotherapy for the treatment of newly diagnosed peripheral T-cell lymphoma (PTCL) patients, also known as mature T-cell lymphoma (MTCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL).

Help employers find you! Check out all the jobs and post your resume.

Back to news